Reducing pathology in Alzheimer’s Disease through Angiotensin taRgeting. The RADAR Trial. A phase II, two arm, double-blind, placebo-controlled, randomised trial to evaluate the effect of losartan on brain tissue changes in patients diagnosed with Alzheimer’s disease. - The RADAR trial in Alzheimer's disease.

orth Bristol NHS Trust0 sites228 target enrollmentJune 20, 2013

Overview

No summary available.

Registry

who.int

Start Date

June 20, 2013

End Date

TBD

Last Updated

7 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

orth Bristol NHS Trust

•Age\=55 years
•A MMSE score of 15\-28 (equivalent to a previous Montreal Cognitive Assessment (MoCA) of 7\-26\). NB all patients must undergo an MMSE as part of their eligibility assessment for RADAR, but may be screened on the basis of a previous MMSE/MoCA score.
•A modified Hachinski score of 5 or less
•A previous CT or MRI scan consistent with a diagnosis of AD
•The presence of an informant who is willing to participate in the study
•Capacity to consent for themselves as judged by a member of the research team with appropriate training and experience
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1\.2 Adults (18\-64 years) yes
•F.1\.2\.1 Number of subjects for this age range 78

•Receiving ACE\-Inhibitors; AT1RAs, aliskiren or potassium sparing diuretics
•Known intolerance or renal problems with ACE\-inhibitors or sartans
•Medically unsuitable for, or unwilling to have, an MRI scan
•Consistent baseline BP of \<115/70 mmHg or \>160/110 mmHg
•A fall in BP on standing of \>20/10 mmHg associated with clinically significant symptoms or a fall \>30/15 mmHg
•Previous cerebrovascular accident (CVA), with significant residual impairment (Transient Ischaemic Attack (TIA) is NOT an exclusion)
•Hypertrophic cardiomyopathy; or significant aortic valve stenosis
•Estimated glomerular filtration rate (eGFR) of \< 30 mL/min/1\.73m2Evidence of liver disease or significant LFT derangement (Aspartate transaminase (AST)/ Alkaline Phosphatase (AP/ALP)/ Bilirubin greater than 2 x upper limit of normal)
•Potassium (K) greater than 6 on non\-haemolysed sample
•Primary neurodegenerative diseases or potential causes of dementia other than AD.